Skip to content
‹ Back to IndustriesHealthcare

Cadence’s RPM Transforms Healthcare Delivery for Patients and Providers

In this episode of 'I Don't Care,' host Dr. Kevin Stevenson speaks with Dr. Ted Feldman, Chief Medical Officer of Cadence, about how the company's remote patient monitoring (RPM) technology helps healthcare systems manage chronic diseases at scale. Cadence's cellular-enabled platform integrates with major EMRs and attaches dedicated care delivery teams to RPM data, reducing clinician burden and hospital readmissions. With 60% of American adults living with at least one chronic condition, the discussion highlights RPM as a critical tool for improving patient outcomes.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

By Kevin Stevenson · · CadenceDr. Ted FeldmanManagement of Chronic DiseasesPatient Outcomes
Share

Key takeaways

01

Cadence's cellular-enabled RPM technology requires no additional devices or apps, simplifying patient enrollment and data collection.

02

Integration with major EMR systems ensures seamless data sharing and continuity of care between Cadence's care teams and health system providers.

03

Cadence attaches advanced practice provider-led care teams to RPM data, delivering guideline-directed medical therapy and reducing hospital readmissions.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As healthcare continues to evolve, the need for efficient management of chronic diseases becomes more pressing. Remote patient monitoring (RPM) emerges as a crucial innovation in this landscape, offering a solution to the rising number of chronic disease cases and the subsequent strain on healthcare systems. A 2023 study found that 60% of American adults have at least one chronic condition, highlighting the urgency for effective management solutions.

60% of American adults have at least one chronic condition, highlighting the urgency for effective management solutions.

Can remote patient monitoring revolutionize chronic disease management, and what are the tangible benefits for patients and healthcare providers?

In the latest episode of I Don’t Care with Dr. Kevin Stevenson, host Dr. Kevin Stevenson engages in a timely discussion with Dr. Ted Feldman, Chief Medical Officer of Cadence. The episode delves into the capabilities and impact of Cadence's RPM technology, which partners with hospitals and health systems to enhance patient outcomes and alleviate clinician workload through advanced practice provider-led clinical care teams.

Key Points of Discussion:

  • Seamless Integration: Cadence's cellular-enabled RPM technology simplifies patient enrollment and data collection without the need for additional devices or applications.
  • Effective Communication: Integration with major electronic medical records (EMRs) ensures that patient data is accessible to healthcare providers, enhancing treatment continuity and decision-making.
  • Care Delivery Teams: Cadence attaches care delivery teams to RPM data, ensuring that patients receive guideline-directed medical therapy (GDMT) and ongoing monitoring, ultimately reducing hospital readmissions and improving clinical outcomes.

Dr. Ted Feldman has over 37 years of experience in interventional cardiology. His career includes pioneering work in percutaneous coronary interventions and significant contributions to clinical trials for chronic disease treatments. As the Chief Medical Officer of Cadence, Dr. Feldman leverages his extensive background to advance the use of technology in chronic disease management.

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Kevin Stevenson
Kevin StevensonTop Hospital Administrator & Healthcare COO, I Don't Care
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

Kevin Stevenson
Kevin Stevenson

Host, I Don't Care with Dr. Kevin Stevenson

I Don't Care

Kevin Stevenson is the host of 'I Don't Care,' a MarketScale podcast focused on the challenges facing healthcare executives and administrators. He engages with industry leaders to explore innovations enabling hospitals, urgent care centers, and telemedicine operators to improve patient care. Stevenson holds an MBA and is a Fellow of the American College of Healthcare Executives (FACHE).

DT
Dr. Ted Feldman

Chief Medical Officer

Cadence

Dr. Theodore Feldman is a board-certified interventional cardiologist with over 37 years of experience, including pioneering work in percutaneous coronary interventions and contributions to clinical trials for chronic disease treatments. As Chief Medical Officer of Cadence, he leads the clinical strategy for the company's remote patient monitoring platform. He holds the designations FACC and FACP.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512